-1752956575380.webp&w=3840&q=75)
2025 NOSCM | Pancreas, Hepatic and Cholangiocarcinoma: Advances in 2025
Overview
Dr. Caio Max Rocha-Lima reviewed 2025 advances in pancreatic, hepatic, and cholangiocarcinoma care. Pre-op therapies showed improved survival, with Pax G outperforming FOLFIRINOX in the Cassandra trial. Panova 3 spotlighted a survival-boosting device. NCCN now backs neoadjuvant care for all risk groups.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Caio Max Rocha-Lima, MD, MS
Date of Release
July 20th, 2025
-1755988787553.webp&w=3840&q=75)
-1755988610269.webp&w=3840&q=75)